This study corroborates previous findings that ICAM-1 upregulation on tumor cells is the IFNγR pathway-dependent, significantly improving CAR T cells’ entry into tumor islets.4 Another study published by the Maus group suggests that IFNγ is not required for CAR T cells against hematologic malignancies. This evidence concerns the gene IFNGR1 and neoplasm.